Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 18/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793017 | 0.91 | GRM4 (0.50) | GRM4CYP1A2 | |
| SCHEMBL19793032 | 0.89 | GRM4 (0.45) | GRM4CYP1A2 | |
| SCHEMBL19793007 | 0.85 | GRM4 (0.47) | GRM4CYP1A2 | |
| SCHEMBL19792970 | 0.85 | GRM4 (0.66) | GRM4CYP1A2 | |
| SCHEMBL19792999 | 0.80 | GRM4 (0.48) | GRM4CYP1A2 | |
| SCHEMBL19793050 | 0.80 | GRM4 (0.41) | GRM4CYP1A2 | |
| SCHEMBL19793188 | 0.80 | GRM4 (0.62) | GRM4CYP1A2CYP2C19 | |
| SCHEMBL19794805 | 0.80 | GRM4 (0.52) | GRM4CYP1A2CYP2C19 | |
| SCHEMBL19793099 | 0.78 | GRM4 (0.51) | GRM4CYP1A2 | |
| SCHEMBL19793020 | 0.77 | GRM4 (0.51) | GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRM1 | GRM4 2/4885CYP1A2 3387/4885TRPA1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.